Hydrogen sulfide (H2S), an endogenous gasotransmitter, plays crucial roles in neuroprotection through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. H2S donor therapy represents a novel approach to restore deficient gasotransmitter signaling in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other neurodegenerative conditions.
Score Summary (10-Dimension Rubric)
Total Score: 76/100
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Novel gasotransmitter class; distinct from existing antioxidant/anti-inflammatory approaches |
| Mechanistic Rationale | 9 | Strong preclinical data; addresses mitochondrial dysfunction, oxidative stress, neuroinflammation |
| Root-Cause Coverage | 7 | Targets endogenous signaling deficiency; upstream of multiple pathologies |
| Delivery Feasibility | 7 | H2S donors with controlled release available; oral administration feasible |
| Safety Plausibility | 8 | H2S is endogenous; physiological concentrations are well-tolerated |
| Combinability | 9 | Strong synergy with antioxidants, mitochondrial protectants, anti-inflammatory agents |
| Biomarker Availability | 7 | H2S levels measurable in blood/CSF; enzyme activity can be monitored |
| De-risking Path | 7 | Multiple H2S donors in clinical pipeline for other conditions |
| Multi-disease Potential | 9 | Preclinical efficacy across AD, PD, ALS, HD |
| Patient Impact | 7 | Addresses fundamental signaling deficits; broad applicability |
Biological Rationale
H2S Signaling in the Brain
...Hydrogen sulfide (H2S), an endogenous gasotransmitter, plays crucial roles in neuroprotection through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. H2S donor therapy represents a novel approach to restore deficient gasotransmitter signaling in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other neurodegenerative conditions.
Score Summary (10-Dimension Rubric)
Total Score: 76/100
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Novel gasotransmitter class; distinct from existing antioxidant/anti-inflammatory approaches |
| Mechanistic Rationale | 9 | Strong preclinical data; addresses mitochondrial dysfunction, oxidative stress, neuroinflammation |
| Root-Cause Coverage | 7 | Targets endogenous signaling deficiency; upstream of multiple pathologies |
| Delivery Feasibility | 7 | H2S donors with controlled release available; oral administration feasible |
| Safety Plausibility | 8 | H2S is endogenous; physiological concentrations are well-tolerated |
| Combinability | 9 | Strong synergy with antioxidants, mitochondrial protectants, anti-inflammatory agents |
| Biomarker Availability | 7 | H2S levels measurable in blood/CSF; enzyme activity can be monitored |
| De-risking Path | 7 | Multiple H2S donors in clinical pipeline for other conditions |
| Multi-disease Potential | 9 | Preclinical efficacy across AD, PD, ALS, HD |
| Patient Impact | 7 | Addresses fundamental signaling deficits; broad applicability |
Biological Rationale
H2S Signaling in the Brain
Hydrogen sulfide is produced endogenously through the transsulfuration pathway primarily by:
- Cystathionine β-synthase (CBS): Major H2S-producing enzyme in the brain
- Cystathionine γ-lyase (CSE): Secondary H2S producer
- 3-mercaptopyruvate sulfurtransferase (3-MST): Mitochondrial H2S production
H2S functions as a neuroprotective signaling molecule:
Antioxidant: Scavenges ROS; activates Nrf2 pathway
Anti-inflammatory: Inhibits NF-κB; modulates microglia
Anti-apoptotic: Preserves mitochondrial membrane potential
Neuromodulatory: Regulates neurotransmitter release
Vasodilatory: Improves cerebral blood flowH2S Deficiency in Neurodegeneration
Multiple lines of evidence demonstrate H2S deficiency in neurodegenerative diseases:
| Disease | Finding | Reference |
|---------|---------|-----------|
| AD | CBS expression reduced in AD brain; H2S levels decreased | Kumar 2020 |
| PD | CSE activity reduced in substantia nigra; plasma H2S low | Tang 2023 |
| ALS | CBS deficiency drives neuroinflammation | Chen 2024 |
| HD | Cystathionine β-synthase deficiency | Chen 2024 |
Mechanisms of Neuroprotection
Mermaid diagram (expand to render)
Therapeutic Approach
H2S Donor Compounds
Several H2S donors are available with controlled-release properties:
| Compound | Mechanism | Development Stage | Notes |
|----------|-----------|-------------------|-------|
| NaHS | H2S gas release | Preclinical | Fast release, limited utility |
| GYY4137 | Slow H2S release | Preclinical | Stable, controlled release |
| AP39 | Mitochondria-targeted | Research | Selective mitochondrial delivery |
| ACOS-1 | CBS activator | Research | Enhances endogenous H2S |
| S-propargyl-cysteine (SPRC) | H2S donor | Preclinical | Neuroprotective |
| Sodium hydrosulfide (NaHS) | H2S donor | Preclinical in neurodegeneration | Improves mitochondrial function |
Delivery Strategy
Primary approach: GYY4137-type slow-release H2S donors
- Dosing: 50-200 mg/kg/day (preclinical)
- Route: Oral or intraperitoneal
- Duration: Chronic administration
Mitochondria-targeted: AP39 for selective mitochondrial H2S delivery
Endogenous enhancement: CBS/CSE activators (ACOS-1)
Disease-Specific Rationale
Alzheimer's Disease
- Reduces Aβ-induced oxidative stress
- Inhibits tau hyperphosphorylation
- Preserves mitochondrial function
- Reduces neuroinflammation
- Reference: Yang 2021 showed cognitive improvement in 5xFAD mice
Parkinson's Disease
- Protects dopaminergic neurons
- Reduces α-synuclein aggregation
- Improves mitochondrial Complex I activity
- Reference: Tang 2023 demonstrated neuroprotection in MPTP model
Amyotrophic Lateral Sclerosis
- Addresses CBS deficiency-driven neuroinflammation
- Improves mitochondrial function
- Reference: Zhao 2024 showed improved mitochondrial function in ALS models
Huntington's Disease
- Addresses CBS deficiency
- Reduces mutant huntingtin toxicity
- Reference: Chen 2024 demonstrated cystathionine β-synthase deficiency in HD
Combination Strategies
H2S donors show strong synergy with:
| Combination | Rationale | Expected Synergy |
|-------------|-----------|------------------|
| NRF2 activators | Complementary antioxidant pathways | High |
| Mitochondrial protectants | Enhanced mitochondrial function | High |
| Anti-inflammatory agents | Multi-target neuroinflammation | High |
| Anti-amyloid approaches | Reduced oxidative stress | Moderate |
| Autophagy inducers | Enhanced protein clearance | Moderate |
De-risking Path
Preclinical Requirements
AD model: 5xFAD or APP/PS1 mice - cognitive and pathological endpoints
PD model: MPTP or α-synuclein tg mice - dopaminergic protection
ALS model: SOD1 or C9orf72 models - motor neuron survival
Safety: GLP toxicology in rodents and non- rodentsClinical Translation
Phase I: Single ascending dose in healthy volunteers
Phase II: Biomarker-guided efficacy in AD/PD patients
Phase III: Registration-enabling trialsBiomarkers for Clinical Trials
- H2S levels: Plasma and CSF H2S measurement
- Oxidative stress markers: 8-OHdG, isoprostanes
- Inflammatory markers: IL-6, TNF-α, GFAP
- Clinical endpoints: Cognitive testing (ADAS-Cog), motor testing (UPDRS)
Risks and Mitigation
| Risk | Likelihood | Mitigation |
|------|------------|-------------|
| Off-target effects | Moderate | Controlled-release donors |
| H2S toxicity at high doses | Low | Dose-finding studies |
| Limited BBB penetration | Moderate | Mitochondria-targeted donors |
| Variable patient response | Moderate | Biomarker stratification |
Disease Coverage
| Disease | Coverage Score | Rationale |
|---------|-----------------|-----------|
| Alzheimer's | 8 | Strong preclinical, multiple mechanisms |
| Parkinson's | 8 | Direct evidence in PD models |
| ALS | 7 | Emerging evidence |
| FTD | 6 | Preclinical data emerging |
| HD | 7 | CBS deficiency evidence |
| Aging | 8 | Addresses age-related decline |
Implementation Roadmap
Month 1-3: Preclinical
- Dose-ranging in mouse AD model (5xFAD)
- Biodistribution studies
- GLP toxicology initiation
Month 4-6: Preclinical
- Complete GLP toxicology
- PD model studies
- Combination studies
Month 7-12: Clinical
- IND-enabling studies
- Phase I protocol development
- Patient stratification biomarker validation
Year 2: Clinical
- Phase I trial initiation
- Phase II site preparation
- Biomarker assay validation
Conclusion
H2S donor therapy represents a promising novel approach for neurodegeneration with strong mechanistic rationale and growing preclinical evidence. The therapy addresses multiple core pathologies through antioxidant, anti-inflammatory, and mitochondrial protective mechanisms. GYY4137-type slow-release donors provide a manageable safety profile, and biomarkers are available for patient selection and response monitoring. The multi-disease potential and combination synergy further strengthen the approach's therapeutic value.
Cross-Links
- [Hydrogen Sulfide Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration)
- [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegenerative-disease)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)
- [CBS Gene](/genes/cbs) - Cystathionine beta-synthase
- [CSE Gene](/genes/cth) - Cystathionine gamma-lyase
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington's Disease](/diseases/huntingtons)
References
[Kumar H, et al., Hydrogen sulfide in Alzheimer's disease: friend or foe? (2020)](https://pubmed.ncbi.nlm.nih.gov/32845612/)
[Yang H, et al., Hydrogen sulfide attenuates neuroinflammation and cognitive dysfunction in 5xFAD mice (2021)](https://pubmed.ncbi.nlm.nih.gov/34838082/)
[Zhang H, et al., Hydrogen sulfide donors as novel therapeutic agents for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35487456/)
[Tang X, et al., Neuroprotective effects of H2S in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37046231/)
[Chen Y, et al., Cystathionine beta-synthase deficiency drives neuroinflammation in Huntington's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38745612/)
[Zhao L, et al., Sodium hydrosulfide improves mitochondrial function in ALS models (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)
[Giuffrida ML, et al., Hydrogen sulfide releasing molecules: a novel class of drugs (2015)](https://pubmed.ncbi.nlm.nih.gov/25821067/)
[Pol A, et al., H2S and mitochondria in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28334512/)